Skip to main content

Table 2 Overview of in vivo studies based on CAR-NK cell therapy for hematological malignancies

From: CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies

Condition Target Main results Ref
B cell malignancies CD19 Prolonged survival in a xenograft Raji lymphoma murine model upon injection iC9/CAR.19/IL-15-transduced CB NK cells which produce IL-15 to improve their function [148]
B cell precursor acute lymphoblastic leukemia CD19 Potent antileukemia activity of human lymphoma in (NSG) xenograft mice model by CAR-CD19-PB NK cells [154]
B cell leukemia and lymphoma CD19 Abrogation of disease progression with selective cytotoxicity against Raji B cell lymphoma xenograft NSG mice model upon injection of NK-92/63.z cells [64]
B cell acute lymphoblastic leukemia (BLL) CD19 Complete molecular remission and prolonged survival in B cell lymphoma xenograft (NSG) mice model by CD19-CAR-NK cells [155]
Lymphoma and leukemia CD19 & CD20 Eradication of TMD-5 (CD19 + CD20+) cells by Intrafemoral injection of CD19-CAR NK-92 and eliminating BCR-ABL1+ SUP-B15 (CD19 + CD20−) cells by intravenous injection of CD19-CAR NK-92 in xenotransplant mouse models
Effective suppressing local tumor development in Daudi lymphoma xenograft mice model by CD20-CAR NK-92 than CD19-CAR NK-92
[158]
B cell non-Hodgkin’s lymphomas (NHL) CD20 Inhibiting MAVER-1 tumor cell growth in xenograft NCG mice model with NK- 92MI cells expressing receptor of CD16-BB-ζ [159]
CD20+ B cell non-Hodgkin’s lymphomas (NHL) CD20 Reducing tumor size and extended survival in Raji-Luc and Raji-2R-Luc xenograft NSG mice model upon injection of CD20-CAR-PB NK cells [160]
Burkitt Lymphoma CD20 The combination of romidepsin and CD20-CAR-PB NK cells reduced tumor burden and enhanced survival in humanized BL in xenograft NSG mice models [161]
Pre-B cell acute lymphoblastic leukemia (B-ALL) FLT3 Abrogated disease progression, high antileukemic activity, and enhancing safety by NK-92 cells co-expressing the FLT3-specific CAR and iCasp9 in a B-ALL xenograft model in NSG mice [162]
T cell acute lymphoblastic leukemia CD5 Abrogated disease progression and improved survival with CD5-CAR-NK-92 cells in xenograft mouse models of CD5+ T-ALL [163]
T cell malignancies CD5 A significant decrease in tumor burden was observed with CD5-CAR-expressing NK-92 cells in a T cell leukemia xenograft mouse model [164]
T cell malignancies CD5 CD5-CAR-NK cells with costimulators 2B4 showed superior cytotoxic ability against T-ALL in mouse xenograft models and prolonged the survival of T-ALL xenograft mice than CD5-CAR-NK with costimulators 4-1BB [98]
T cell non-Hodgkin’s lymphomas (NHLs) CD4 CD4-CAR-NK-92 cells significantly reduced tumor burden and prolonged survival in KARPAS-299-injected NSG mice [165]
Multiple myeloma CS1 Suppressing the growth of human IM9 MM cells and also significantly prolonged survival in an aggressive orthotopic MM xenograft mouse model upon injection of CS1-CAR-NK-92 cells [166]
Multiple myeloma CD138 Marked antitumor activity toward CD138+ MM cells in the xenograft SCID mouse model by CD138-CAR-NK-92MI cells [167]
Acute myeloid leukemia (AML) CD123 Significantly reduced disease burden in NSG mice xenografted with luciferase-expressing THP-1 cells upon injection of CD123-CAR-NK-92 [171]
Acute myeloid leukemia (AML) CD4 Antileukemic effects in a systemic AML murine model with CD4-CAR-PB NK cells [173]